JP2019502360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502360A5 JP2019502360A5 JP2018516122A JP2018516122A JP2019502360A5 JP 2019502360 A5 JP2019502360 A5 JP 2019502360A5 JP 2018516122 A JP2018516122 A JP 2018516122A JP 2018516122 A JP2018516122 A JP 2018516122A JP 2019502360 A5 JP2019502360 A5 JP 2019502360A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- nos
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021201297A JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265615P | 2015-12-10 | 2015-12-10 | |
| GBGB1521746.6A GB201521746D0 (en) | 2015-12-10 | 2015-12-10 | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| US62/265,615 | 2015-12-10 | ||
| GB1521746.6 | 2015-12-10 | ||
| PCT/EP2016/078718 WO2017097602A1 (en) | 2015-12-10 | 2016-11-24 | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021201297A Division JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502360A JP2019502360A (ja) | 2019-01-31 |
| JP2019502360A5 true JP2019502360A5 (enExample) | 2020-01-30 |
| JP7053457B2 JP7053457B2 (ja) | 2022-04-12 |
Family
ID=55274485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516122A Expired - Fee Related JP7053457B2 (ja) | 2015-12-10 | 2016-11-24 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2021201297A Pending JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021201297A Pending JP2022058349A (ja) | 2015-12-10 | 2021-12-11 | Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (25)
| Country | Link |
|---|---|
| US (14) | US10064928B2 (enExample) |
| EP (1) | EP3387008A1 (enExample) |
| JP (2) | JP7053457B2 (enExample) |
| KR (1) | KR20180086190A (enExample) |
| CN (1) | CN108602867A (enExample) |
| AR (1) | AR106920A1 (enExample) |
| AU (3) | AU2016368981B2 (enExample) |
| BR (1) | BR112018007206A2 (enExample) |
| CA (1) | CA3005813A1 (enExample) |
| CL (6) | CL2018001532A1 (enExample) |
| CO (1) | CO2018004865A2 (enExample) |
| CR (6) | CR20200592A (enExample) |
| EA (1) | EA201891074A1 (enExample) |
| GB (1) | GB201521746D0 (enExample) |
| HK (1) | HK1259376A1 (enExample) |
| IL (1) | IL259304A (enExample) |
| MA (2) | MA42072A1 (enExample) |
| MX (1) | MX2018005372A (enExample) |
| PE (1) | PE20181075A1 (enExample) |
| PH (1) | PH12018500848A1 (enExample) |
| SG (3) | SG10202111398UA (enExample) |
| TW (2) | TWI730306B (enExample) |
| UA (1) | UA124575C2 (enExample) |
| WO (1) | WO2017097602A1 (enExample) |
| ZA (1) | ZA201801752B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102639592B1 (ko) | 2016-12-08 | 2024-02-21 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| CN111533799A (zh) | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于白血病和其他癌症免疫治疗的肽和肽组合物 |
| ES2898210T3 (es) | 2017-07-14 | 2022-03-04 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN108079285B (zh) * | 2018-02-06 | 2021-01-01 | 昆明龙津药业股份有限公司 | 用于蛇毒酶制剂的门冬氨酸稳定剂及制备方法 |
| MX2020008327A (es) | 2018-02-09 | 2020-10-28 | Immatics Us Inc | Metodos para preparar celulas t. |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| CN114174323B (zh) * | 2019-07-05 | 2025-01-07 | 弗朗西斯·克里克研究所有限公司 | 新的癌抗原和方法 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20230158132A1 (en) * | 2020-04-14 | 2023-05-25 | Universite De Montreal | Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof |
| EP3907284A1 (en) * | 2020-05-06 | 2021-11-10 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and combinations of peptides for use in immunotherapy against hematologic neoplasms and other cancers |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Ｃｄ８多肽、組合物及其使用方法 |
| JP2024516699A (ja) | 2021-05-05 | 2024-04-16 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｂｍａ０３１抗原結合ポリペプチド |
| US20240358831A1 (en) | 2021-08-24 | 2024-10-31 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2024223849A1 (en) * | 2023-04-27 | 2024-10-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Neoepitope immunogenic peptides for cancer treatment and diagnosis |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029193A2 (en) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
| US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20040000556A1 (en) * | 2003-01-25 | 2004-01-01 | Harris Jennifer Hope | Trash receptacles that use plastic grocery bags as liners and methods of advertising |
| EP1627076A4 (en) | 2003-03-14 | 2008-07-02 | Ppd Biomarker Discovery Scienc | BIOLOGICAL MARKERS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS |
| JP2007519910A (ja) * | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 腫瘍関連ペプチドの同定および定量方法 |
| ES2319286T3 (es) | 2004-10-02 | 2009-05-06 | Immatics Biotechnologies Gmbh | Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos. |
| US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| WO2007103770A2 (en) | 2006-03-02 | 2007-09-13 | Ppd Biomarker Discovery Sciences, Llc | Compositions and methods for analyzing renal cancer |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| CN102066410B (zh) * | 2007-11-01 | 2017-01-18 | 梅约医学教育与研究基金会 | Hla‑dr结合肽和它们的应用 |
| DK2119726T5 (en) * | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| WO2010002911A2 (en) * | 2008-06-30 | 2010-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods and materials for monitoring myeloma using quantitative mass spetrometry |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| WO2011027311A2 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| WO2011027308A1 (en) | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| EP2330122A1 (en) * | 2009-12-02 | 2011-06-08 | Asklepios Kliniken Hamburg Gmbh | OFA/iLRP derived modified peptide |
| WO2011073905A1 (en) * | 2009-12-14 | 2011-06-23 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| NZ609916A (en) * | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013019634A1 (en) | 2011-07-29 | 2013-02-07 | University Of Georgia Research Foundation, Inc. | Alpha toxin detection of gpi anchored proteins |
| WO2013037972A1 (en) * | 2011-09-16 | 2013-03-21 | Pamgene B.V. | Method for predicting response to endocrine therapy |
| CA2880331A1 (en) * | 2012-08-15 | 2014-02-20 | Universite De Montreal | Method for identifying novel minor histocompatibility antigens |
| TWI819228B (zh) | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MA42294B1 (fr) * | 2015-07-01 | 2020-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
-
2015
- 2015-12-10 GB GBGB1521746.6A patent/GB201521746D0/en not_active Ceased
-
2016
- 2016-11-24 PE PE2018000324A patent/PE20181075A1/es unknown
- 2016-11-24 JP JP2018516122A patent/JP7053457B2/ja not_active Expired - Fee Related
- 2016-11-24 KR KR1020187013544A patent/KR20180086190A/ko not_active Withdrawn
- 2016-11-24 BR BR112018007206-0A patent/BR112018007206A2/pt not_active IP Right Cessation
- 2016-11-24 EP EP16805348.6A patent/EP3387008A1/en not_active Withdrawn
- 2016-11-24 SG SG10202111398UA patent/SG10202111398UA/en unknown
- 2016-11-24 CR CR20200592A patent/CR20200592A/es unknown
- 2016-11-24 CR CR20200594A patent/CR20200594A/es unknown
- 2016-11-24 CR CR20200593A patent/CR20200593A/es unknown
- 2016-11-24 CR CR20200596A patent/CR20200596A/es unknown
- 2016-11-24 WO PCT/EP2016/078718 patent/WO2017097602A1/en not_active Ceased
- 2016-11-24 MA MA42072A patent/MA42072A1/fr unknown
- 2016-11-24 UA UAA201803219A patent/UA124575C2/uk unknown
- 2016-11-24 CR CR20200595A patent/CR20200595A/es unknown
- 2016-11-24 AU AU2016368981A patent/AU2016368981B2/en not_active Ceased
- 2016-11-24 SG SG11201801670YA patent/SG11201801670YA/en unknown
- 2016-11-24 EA EA201891074A patent/EA201891074A1/ru unknown
- 2016-11-24 HK HK19101744.6A patent/HK1259376A1/zh unknown
- 2016-11-24 CR CR20180295A patent/CR20180295A/es unknown
- 2016-11-24 MA MA043399A patent/MA43399A/fr unknown
- 2016-11-24 CA CA3005813A patent/CA3005813A1/en not_active Abandoned
- 2016-11-24 MX MX2018005372A patent/MX2018005372A/es unknown
- 2016-11-24 SG SG10202005498VA patent/SG10202005498VA/en unknown
- 2016-11-24 CN CN201680071930.3A patent/CN108602867A/zh active Pending
- 2016-12-06 AR ARP160103738A patent/AR106920A1/es not_active Application Discontinuation
- 2016-12-09 TW TW108109253A patent/TWI730306B/zh not_active IP Right Cessation
- 2016-12-09 US US15/374,054 patent/US10064928B2/en active Active
- 2016-12-09 TW TW105140762A patent/TWI658050B/zh not_active IP Right Cessation
- 2016-12-09 US US15/374,480 patent/US10117916B2/en active Active
- 2016-12-09 US US15/375,070 patent/US10398766B2/en active Active
-
2018
- 2018-03-14 ZA ZA2018/01752A patent/ZA201801752B/en unknown
- 2018-04-20 PH PH12018500848A patent/PH12018500848A1/en unknown
- 2018-05-08 CO CONC2018/0004865A patent/CO2018004865A2/es unknown
- 2018-05-13 IL IL259304A patent/IL259304A/en unknown
- 2018-06-08 CL CL2018001532A patent/CL2018001532A1/es unknown
- 2018-08-03 US US16/054,503 patent/US11083784B2/en not_active Expired - Fee Related
- 2018-08-22 US US16/109,427 patent/US10238725B2/en active Active
- 2018-08-22 US US16/109,451 patent/US10335474B2/en active Active
- 2018-08-22 US US16/109,406 patent/US10238724B2/en active Active
- 2018-08-22 US US16/109,436 patent/US10238726B2/en active Active
-
2019
- 2019-05-17 US US16/415,671 patent/US10653762B2/en active Active
- 2019-05-17 US US16/415,655 patent/US10653761B2/en active Active
- 2019-10-31 US US16/669,622 patent/US10722566B2/en active Active
-
2020
- 2020-07-30 CL CL2020001989A patent/CL2020001989A1/es unknown
- 2020-07-30 CL CL2020001985A patent/CL2020001985A1/es unknown
- 2020-07-30 CL CL2020001987A patent/CL2020001987A1/es unknown
- 2020-07-30 CL CL2020001988A patent/CL2020001988A1/es unknown
- 2020-07-30 CL CL2020001986A patent/CL2020001986A1/es unknown
- 2020-12-03 AU AU2020281108A patent/AU2020281108B2/en not_active Ceased
-
2021
- 2021-05-14 US US17/320,854 patent/US11260115B1/en active Active
- 2021-12-11 JP JP2021201297A patent/JP2022058349A/ja active Pending
-
2022
- 2022-01-31 AU AU2022200616A patent/AU2022200616A1/en not_active Abandoned
- 2022-02-04 US US17/665,117 patent/US20220226450A1/en not_active Abandoned
-
2024
- 2024-04-26 US US18/647,775 patent/US20240285738A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502360A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2018519243A5 (enExample) | ||
| JP2018518937A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2024099580A5 (enExample) | ||
| JP2018521641A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2020530759A5 (enExample) | ||
| JP2017524337A5 (enExample) | ||
| JP2019516663A5 (enExample) | ||
| AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| JP2020516681A5 (enExample) |